APA (7th ed.) Citation

HC, C., E, S., F, L., E, Y., SA, I., E, C., . . . I, K. (2024). Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study. Cancer, 130(19), 3278. https://doi.org/10.1002/cncr.35387

Chicago Style (17th ed.) Citation

HC, Chung, et al. "Lenvatinib Plus Pembrolizumab for Patients with Previously Treated, Advanced, Triple-negative Breast Cancer: Results from the Triple-negative Breast Cancer Cohort of the Phase 2 LEAP-005 Study." Cancer 130, no. 19 (2024): 3278. https://doi.org/10.1002/cncr.35387.

MLA (9th ed.) Citation

HC, Chung, et al. "Lenvatinib Plus Pembrolizumab for Patients with Previously Treated, Advanced, Triple-negative Breast Cancer: Results from the Triple-negative Breast Cancer Cohort of the Phase 2 LEAP-005 Study." Cancer, vol. 130, no. 19, 2024, p. 3278, https://doi.org/10.1002/cncr.35387.